MED10 as a Novel Oncogenic Driver in HCC: Promoting Cell Cycle Progression and Proliferation Through RAF1 Activation
MED10 promotes HCC cell migration and EMT but, more importantly, also drives cell cycle progression and proliferation via RAF1 activation, and is related to the MEK/ERK/c-Myc axis.
Authors
- Ke-Jun Liu (ORCID: https://orcid.org/0000-0001-5770-7865)
- Zhengquan Li (ORCID: https://orcid.org/0000-0002-0084-5113)
- Yongxue Lv (ORCID: https://orcid.org/0000-0002-9095-0469)
- Bendong Chen (ORCID: https://orcid.org/0009-0001-5618-6962)
- Yang Bu (ORCID: https://orcid.org/0000-0003-1219-997X)
- Junhao Liu (ORCID: https://orcid.org/0009-0003-2705-5124)
Institutions
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-08-29
- DOI
- https://doi.org/10.31083/fbl39944
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Ningxia Province